To evaluate the role of allergen immunotherapy (AIT) in the treatment of allergic rhinitis (AR).
Method
Individual studies, systematic reviews, and practice guidelines that included information on sublingual AIT (SLIT) and subcutaneous AIT (SOT) in the treatment of AR were considered.
Results
AIT via the SLIT or SCIT route has been shown to be effective in treating AR symptoms with resultant improvements in overall quality of life, comorbid illnesses, and medication requirements. Persistent clinical benefits have been demonstrated years after AIT treatment discontinuation. AIT may prevent the progression of AR to asthma. In addition, studies that evaluated the pharmacoeconomics of AR treatment indicate that AIT may be more cost effective than pharmacotherapy. The AIT cost savings are likely underestimated in that few cost comparison studies considered AIT's long-term benefits or preventive effects.
Conclusion
Multiple individual studies and systematic reviews provide strong evidence for the clinical effectiveness of AIT in the treatment of AR. Cost-effectiveness and disease modification are additional advantages of AIT compared with standard drug treatment in the management of AR.
Get full access to this article
View all access options for this article.
References
1.
BurgessJ.A.WaltersE.H.ByrnesG.B.Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: A longitudinal study.J Allergy Clin Immunol120: 863–869, 2007
2.
Baena-CagnaniC.E.CanonicaG.W.Zaky HelalM.The international survey on the management of allergic rhinitis by physicians and patients (ISMAR).World Allergy Organ J8: 10, 2015
3.
Kreiner-MollerE.ChawesB.L.Caye-ThomasenP.BonnelykkeK.BisgaardH.Allergic rhinitis is associated with otitis media with effusion: a birth cohort study.Clin Exp Allergy42: 1615–1620, 2012
4.
OzdoganogluT. and SonguM.The burden of allergic rhinitis and asthma.Ther Adv Respir Dis6: 11–23, 2012
5.
ValovirtaE. (Ed). EFA Book on Respiratory Allergies.Brussels, Belgium: European Federation of Allergy and Airways Diseases Patients Associations, 2011
6.
WallaceD.V.DykewiczM.S.BernsteinD.I.The diagnosis and management of rhinitis: An updated practice parameter.J Allergy Clin Immunol122: S1–S84, 2008
BauchauV. and DurhamS.R.Prevalence and rate of diagnosis of allergic rhinitis in Europe.Eur Respir J24: 758–764, 2004
9.
BunyavanichS.Soto-QuirosM.E.AvilaL.Risk factors for allergic rhinitis in Costa Rican children with asthma.Allergy65: 256–263, 2010
10.
MaurerM. and ZuberbierT.Undertreatment of rhinitis symptoms in Europe: Findings from a cross-sectional questionnaire survey.Allergy62: 1057–1063, 2007
11.
SazonovV.AmbegaonkarB.M.BolgeS.C.Frequency of diagnosis and treatment of allergic rhinitis among adults with asthma in Germany, France, and the UK: National Health and Wellness Survey.Curr Med Res Opin25: 1721–1726, 2009
12.
NolteH.Nepper-ChristensenS. and BackerV.Unawareness and undertreatment of asthma and allergic rhinitis in a general population.Respir Med100: 354–362, 2006
13.
SoniA.Medical Expenditure Panel Survey.Statistical Brief no. 204: Allergic Rhinitis: Trends in Use and Expenditures, 2000 and 2005.Bethesda, MD: Agency for Healthcare Research and Quality, 2008. Available online at meps.ahrq.gov/mepsweb/data_files/publications/st204/stat204.pdf; accessed May 26, 2015
14.
BlaissM.S.Allergic rhinitis: Direct and indirect costs.Allergy Asthma Proc31: 375–380, 2010
15.
SchultzA.B.ChenC.Y. and EdingtonD.W.The cost and impact of health conditions on presenteeism to employers: A review of the literature.Pharmacoeconomics27: 365–378, 2009
16.
SchoenwetterW.F.DupclayL.Jr., AppajosyulaS.Economic impact and quality-of-life burden of allergic rhinitis.Curr Med Res Opin20: 305–317, 2004
17.
LambC.E.RatnerP.H.JohnsonC.E.Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective.Curr Med Res Opin22: 1203–1210, 2006
18.
SheikhA.HurwitzB.NurmatovU. and van SchayckC.P.House dust mite avoidance measures for perennial allergic rhinitis.Cochrane Database Syst Rev (7): CD001563, 2010
19.
GotzscheP.C. and JohansenH.K.House dust mite control measures for asthma.Cochrane Database Syst Rev (2): CD001187, 2008
20.
WoodR.A.ChapmanM.D.AdkinsonN.F.Jr., and EgglestonP.A.The effect of cat removal on allergen content in household-dust samples.J Allergy Clin Immunol83: 730–734, 1989
21.
ArbesS.J.Jr., CohnR.D.YinM.Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: Results from the National Survey of Lead and Allergens in Housing.J Allergy Clin Immunol114: 111–117, 2004
22.
ArbesS.J.Jr., SeverM.ArcherJ.Abatement of cockroach allergen (Bla g 1) in low-income, urban housing: A randomized controlled trial.J Allergy Clin Immunol112: 339–345, 2003
23.
MorganW.J.CrainE.F.GruchallaR.S.Results of a home-based environmental intervention among urban children with asthma.N Engl J Med351: 1068–1080, 2004
24.
PhipatanakulW.MatsuiE.PortnoyJ.Environmental assessment and exposure reduction of rodents: A practice parameter.Ann Allergy Asthma Immunol109: 375–387, 2012
25.
PortnoyJ.KennedyK.SublettJ.Environmental assessment and exposure control: A practice parameter-furry animals.Ann Allergy Asthma Immunol108: 223.e1–15, 2012
26.
PortnoyJ.MillerJ.D.WilliamsP.B.Environmental assessment and exposure control of dust mites: A practice parameter.Ann Allergy Asthma Immunol111: 465–507, 2013
27.
GuilbertT.W.MorganW.J.ZeigerR.S.Long-term inhaled corti-costeroids in preschool children at high risk for asthma.N Engl J Med354: 1985–1997, 2006
28.
StrunkR.C.SternbergA.L.SzeflerS.J.Long-term budesonide or nedocromil treatment, once discontinued, does not alter the course of mild to moderate asthma in children and adolescents.J Pediatr154: 682–687, 2009
29.
DurhamS.R.EmmingerW.KappA.SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.J Allergy Clin Immunol129: 717–725.e5, 2012
30.
MarognaM.SpadoliniI.MassoloA.Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study.J Allergy Clin Immunol126: 969–975, 2010
31.
AkdisM. and AkdisC.A.Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens.J Allergy Clin Immunol133: 621–631, 2014
32.
Des RochesA.ParadisL.MenardoJ.L.Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific im-munotherapy prevents the onset of new sensitizations in children.J Allergy Clin Immunol99: 450–453, 1997
33.
JacobsenL.NiggemannB.DreborgS.Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.Allergy62: 943–948, 2007
34.
NovembreE.GalliE.LandiF.Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis.J Allergy Clin Immunol114: 851–857, 2004
35.
MoingeonP.Update on immune mechanisms associated with sub-lingual immunotherapy: Practical implications for the clinician.J Allergy Clin Immunol Pract1: 228–241, 2013
36.
BurksA.W.CalderonM.A.CasaleT.Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRAC-TALL consensus report.J Allergy Clin Immunol131: 1288–1296.e3, 2013
37.
CanonicaG.W.CoxL.PawankarR.Sublingual immunotherapy: World Allergy Organization position paper 2013 update.World Allergy Organ J7: 6, 2014
38.
RadulovicS.WilsonD.CalderonM. and DurhamS.Systematic reviews of sublingual immunotherapy (SLIT).Allergy66: 740–752, 2011
HowarthP.MallingH.J.MolimardM. and DevillierP.Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients.Allergy67: 321–327, 2012
41.
VarneyV.A.GagaM.FrewA.J.Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs.BMJ302: 265–269, 1991
42.
NoonL.Prophylactic inoculation against hay fever.Lancet1: 15721573, 1911
43.
CoxL.Sublingual immunotherapy for aeroallergens: Status in the United States.Allergy Asthma Proc35: 34–42, 2014
44.
CoxL. and JacobsenL.Comparison of allergen immunotherapy practice patterns in the United States and Europe.Ann Allergy Asthma Immunol103: 451–459; quiz 459-461, 495, 2009
45.
Sikora JM, Tankersley MS, and ACAAI Immunotherapy and Diagnostics Committee.Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey.Ann Allergy Asthma Immunol110: 194–7.e4, 2013
46.
TuckerM.H. and TankersleyM.S.Perception and practice of sublin-gual immunotherapy among practicing allergists.Ann Allergy Asthma Immunol101: 419–425, 2008
CoxL.NelsonH.LockeyR.Allergen immunotherapy: A practice parameter third update.J Allergy Clin Immunol127: S1–S55, 2011
52.
SchneiderL.TillesS.LioP.Atopic dermatitis: A practice parameter update 2012.J Allergy Clin Immunol131: 295–299.e1-27, 2013
53.
BaeJ.M.ChoiY.Y.ParkC.O.Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials.J Allergy Clin Immunol132: 110–117, 2013
54.
NarisetyS.D.Frischmeyer-GuerrerioP.A.KeetC.A.A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.J Allergy Clin Immunol135: 1275–1282.e6, 2015
55.
BurksA.W.JonesS.M.WoodR.A.Oral immunotherapy for treatment of egg allergy in children.N Engl J Med367: 233–243, 2012
56.
BurksA.W.WoodR.A.JonesS.M.Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.J Allergy Clin Immunol135: 1240–1248.e1-3, 2015
57.
PajnoG.B.CoxL.CaminitiL.Oral immunotherapy for treatment of immunoglobulin e-mediated food allergy: The transition to clinical practice.Pediatr Allergy Immunol Pulmonol27: 42–50, 2014
58.
WoodR.A. and SampsonH.A.Oral immunotherapy for the treatment of peanut allergy: Is it ready for prime time?J Allergy Clin Immunol Pract2: 97–98, 2014
59.
CoopC.A. and TankersleyM.S.Patient perceptions regarding local reactions from allergen immunotherapy injections.Ann Allergy Asthma Immunol101: 96–100, 2008
60.
CoxL.S.Larenas-LinnemannD.NolteH.Sublingual immunotherapy: A comprehensive review.J Allergy Clin Immunol117: 1021–1035, 2006
61.
CoxL.Larenas-LinnemannD.LockeyR.F. and PassalacquaG.Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System.J Allergy Clin Immunol125: 569–574, 574.e1-574.e7, 2010
62.
EpsteinT.G.LissG.M.Murphy-BerendtsK. and BernsteinD.I.AAAAI/ACAAI Surveillance study of subcutaneous immunotherapy, years 2008-2012: An update on fatal and nonfatal systemic allergic reactions.J Allergy Clin Immunol Pract2: 161–167.e3, 2014
63.
BernsteinD.I.EpsteinT.Murphy-BerendtsK. and LissG.M.Surveillance of systemic reactions to subcutaneous immunotherapy injections: Year 1 outcomes of the ACAAI and AAAAI collaborative study.Ann Allergy Asthma Immunol104: 530–535, 2010
64.
AminH.S.LissG.M. and BernsteinD.I.Evaluation of near-fatal reactions to allergen immunotherapy injections.J Allergy Clin Immunol117: 169–175, 2006
CalderonM.A.SimonsF.E.MallingH.J.Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile.Allergy67: 302–11, 2012
67.
Alvarez-CuestaE.BousquetJ.CanonicaG.W.Standards for practical allergen-specific immunotherapy.Allergy61(suppl. 82): 1–20, 2006
68.
CoxL.S.HankinC. and LockeyR.Allergy immunotherapy adherence and delivery route: Location does not matter.J Allergy Clin Immunol Pract2: 156–160, 2014
69.
BenderB.G. and OppenheimerJ.The special challenge of nonadher-ence with sublingual immunotherapy.J Allergy Clin Immunol Pract2: 152–155, 2014
70.
IncorvaiaC.RapettiA.ScuratiS.Importance of patient's education in favouring compliance with sublingual immunotherapy.Allergy65: 1341–1342, 2010
71.
VitaD.CaminitiL.RuggeriP. and PajnoG.B.Sublingual immuno-therapy: Adherence based on timing and monitoring control visits.Allergy65: 668–669, 2010
72.
CreticosP.S.EschR.E.CourouxP.Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis.J Allergy Clin Immunol133: 751–758, 2014
73.
MatricardiP.M.KunaP.PanettaV.Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses.J Allergy Clin Immunol128: 791–799.e6, 2011
74.
CoxL.Allergy immunotherapy in reducing healthcare cost.Curr Opin Otolaryngol Head Neck Surg23: 247–254, 2015
75.
ArianoR.BertoP.TracciD.Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma.Allergy Asthma Proc27: 159–163, 2006
76.
MeadowsA.KaambwaB.NovielliN.A systematic review and economic evaluation of subcutaneous and sublingual allergen immu-notherapy in adults and children with seasonal allergic rhinitis.Health Technol Assess17: vi, xi-xiv, 1-322, 2013
77.
HankinC.S. and CoxL.Allergy immunotherapy: What is the evidence for cost saving?Curr Opin Allergy Clin Immunol14: 363–370, 2014
78.
HankinC.S.CoxL.BronstoneA. and WangZ.Allergy immunotherapy: Reduced health care costs in adults and children with allergic rhinitis.J Allergy Clin Immunol131: 1084–1091, 2013
79.
HankinC.S.CoxL.LangD.Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: A large-scale, retrospective, matched cohort study.Ann Allergy Asthma Immunol104: 79–85, 2010
80.
HankinC.S.CoxL.LangD.Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs.J Allergy Clin Immunol121: 227–232, 2008
81.
NelsonH.S.Multiallergen immunotherapy for allergic rhinitis and asthma.J Allergy Clin Immunol123: 763–769, 2009
82.
CalderonM.A.CoxL.CasaleT.B.Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence.J Allergy Clin Immunol129: 929–934, 2012
83.
CalderonM.A. and CoxL.S.Monoallergen sublingual immunotherapy versus multiallergen subcutaneous immunotherapy for allergic respiratory diseases: A debate during the AAAAI 2013 Annual Meeting in San Antonio, Texas.J Allergy Clin Immunol Pract2: 136–143, 2014
84.
CopenhaverC.C.ParkerA. and PatchS.Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice.Ann Allergy Asthma Immunol107: 441–447, 2011
